AUSTIN, Texas--(BUSINESS WIRE)--Apollo Endosurgery, Inc. (“Apollo”) (NASDAQ:APEN), a leader in less invasive surgical medical devices for bariatric and gastrointestinal procedures, announced today U.S ...
OverStitch has new indications for use statement under CE-Mark, including indications for defect closure, stent fixation, endoscopic sleeve gastroplasty and transoral outlet reduction AUSTIN, TX / ...
AUSTIN, TX--(Marketwired - Apr 2, 2013) - Apollo Endosurgery, Inc., a company focused on the development of devices that enable a new generation of endoscopic surgical procedures, announced that its ...
Apollo's products are offered in over 75 countries today and include the X-Tack Endoscopic HeliX Tacking System, the OverStitch Endoscopic Suturing System, the OverStitch Sx Endoscopic Suturing System ...
Shares of Apollo Endosurgery Inc. rocketed 28% in premarket trade Tuesday, after the medical device company said the Food and Drug Administration cleared its new flexibile endoscopic suturing system, ...
AUSTIN, Texas--(BUSINESS WIRE)--Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, announced today that ...
AUSTIN, TX / ACCESSWIRE / May 24, 2021 / Apollo Endosurgery, Inc. ("Apollo") (Nasdaq:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, ...
OverStitch has new indications for use statement under CE-Mark, including indications for defect closure, stent fixation, endoscopic sleeve gastroplasty and transoral outlet reduction AUSTIN, TX / ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback